• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by KORU Medical Systems Inc.

    8/12/25 6:54:59 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care
    Get the next $KRMD alert in real time by email
    S-8 1 form_s-8.htm FORM S-8 REGISTRATION STATEMENT

     

    As filed with the Securities and Exchange Commission on August 12, 2025

     

    Registration No. 333-______

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

     

    KORU Medical Systems, Inc.
    (Exact name of registrant as specified in its charter)

     

     

    Delaware   13-3044880
    (State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification No.)

     

     

    100 Corporate Drive

    Mahwah, NJ

      07430
    (Address of Principal Executive Offices)   (Zip Code)

     

     

    Individual Non-Qualified Stock Option Award (Time-Based)

    Individual Restricted Stock Agreement (Time-Based)

    (Full Title of the Plans)

     

     

    Copies of all correspondence to:

     

    Heather R. Badami, Esq.

    Royer Cooper Cohen Braunfeld LLC

    Three Logan Square

    1717 Arch Street, Suite 4700

    Philadelphia, PA 19103

    (Name and address of agent for service)

     

    (215) 839-1000
    (Telephone number, including area code, of agent for service)

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer  ☐   Accelerated filer  ☐
    Non-accelerated filer    ☒   Smaller reporting company ☒
        Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     


     

    EXPLANATORY NOTE

     

    Pursuant to an individual Restricted Stock Agreement (time-based) and an individual Non-Qualified Stock Option Award (time-based), the Registrant was granted 300,000 shares of restricted Common Stock and options covering 600,000 shares of Common Stock, respectively, on July 28, 2025 and August 1, 2025, respectively, each subject to vesting and acceleration thereof, to Adam Kalbermatten as a material inducement to Mr. Kalbermatten’s acceptance of employment as the Chief Commercial Officer of the Registrant. This Registration Statement registers the Common Stock issuable upon exercise of such options. The inclusion of such shares herein does not necessarily represent a present intention of Mr. Kalbermatten to sell any or all such shares of Common Stock.

     

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    As permitted by the rules of the Securities and Exchange Commission (the “Commission”), this Registration Statement omits the information specified in Part I of Form S-8. The documents containing the information specified in Part I will be delivered to the participant as required by Rule 428(b)(1) under the Securities Act of 1933, as amended (the “Securities Act”).

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents filed by the Registrant with the Commission pursuant to the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated by reference herein:

     

    ●     The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on March 12, 2025;

     

    ●     All other reports filed by the Registrant pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Registrant’s Annual Report referred to in (a) above;

     

    ●     The description of the Registrant’s common stock set forth in our Form 8-A12B/A filed with the Commission on May 17, 2023.

     

    All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, after the date of this Registration Statement and prior to the filing of a post-effective amendment that indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, are incorporated by reference in this Registration Statement and are a part hereof from the date of filing of such documents; except as to any portion of any future annual or quarterly report to stockholders or document or current report furnished under current Items 2.02 or 7.01 of Form 8-K that is not deemed filed under such provisions. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Any statement contained herein or in a document incorporated or deemed to be incorporated by reference in this Registration Statement shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in this Registration Statement, or in any other subsequently filed document which also is or is deemed to be incorporated by reference in this Registration Statement, modifies or supersedes such earlier statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    - 2 -


     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 6. Indemnification of Directors and Officers.

     

    Our certificate of incorporation includes a provision that eliminates the personal liability of directors for monetary damages for any breach of fiduciary duty as a director, except where such liability is imposed under the Delaware General Corporation Law (the “DGCL”). The DGCL provides that a corporation may indemnify an individual made a party to a proceeding because he is or was a director against liability incurred in the proceeding unless (i) the act or omission was material to the matter giving rise to the proceeding and was committed in bad faith or was the result of active and deliberate dishonesty; (ii) the director actually received an improper personal benefit; or (iii) in the case of any criminal proceeding, the director had reasonable cause to believe the act or omission was unlawful, provided however, that if the proceeding was by or in the right of the corporation, no indemnification may be made if the director is adjudged liable to the corporation. The Board of Directors of the Registrant (the “Board”) may also indemnify an employee or agent of the corporation who was or is a party to any proceeding by reason of the fact that he is or was an employee or agent of the corporation.

     

    Our certificate of incorporation and bylaws provide that, to the maximum extent permitted by Delaware law and the federal securities laws, we must indemnify and, upon request advance, expenses to a director or officer made, or threatened to be made, a party to any action or proceeding (other than a shareholder derivative action) by reason of such person being a director or officer, if such director or officer acted in good faith for a purpose which he or she reasonably believed to be in, or not opposed to, the best interests of the corporation and, in criminal actions or proceedings, in addition, had no reasonable cause to believe that his or her conduct was unlawful. Indemnification would cover reasonable expenses, including attorneys' fees, judgments, fines, amounts paid in settlement.

     

    The limitation of liability, indemnification and advancement provisions in our certificate of incorporation and bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against directors and officers.

     

    Insofar as indemnification for liabilities arising under the Securities Act, may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been advised that in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

    Item 7. Exemption for Registration Claimed.

     

    Not applicable.

     

    - 3 -


     

    Item 8. Exhibits.

     

    Exhibit
    Number
      Description
         
    3.1   Certificate of Incorporation of the Registrant effective May 16, 2023 (incorporated by reference to the Registrant’s Form 8-K, filed with the Securities and Exchange Commission on May 17, 2023).
         
    3.2   By-laws of the Registrant dated May 16, 2023 (incorporated by reference to the Registrant’s Form 8-K, filed with the Securities and Exchange Commission on May 17, 2023).
         
    4.1   Description of Registrant’s Securities registered pursuant to Section 12 of the Securities Exchange Act of 1934 (incorporated by reference to the Registrant’s Form 8-A12B/A filed with the Commission on May 17, 2023).
         
    5.1   Opinion of Royer Cooper Cohen Braunfeld LLC (filed herewith)
         
    23.1   Consent of Independent Registered Public Accounting Firm (filed herewith)
         
    23.2   Consent of Royer Cooper Cohen Braunfeld LLC (included in Exhibit 5.1)
         
    24.1   Power of Attorney (included in signature page)
         
    99.1   Non-Qualified Stock Option Award (time-based vesting) between KORU Medical Systems, Inc. and Adam Kalbermatten (incorporated by reference to the Registrant’s Form 10-Q, filed with the Securities and Exchange Commission on August 6, 2025)
         
    99.2   Restricted Stock Agreement (time-based vesting) between KORU Medical Systems, Inc. and Adam Kalbermatten (incorporated by reference to the Registrant’s Form 10-Q, filed with the Securities and Exchange Commission on August 6, 2025)
         
    107   Filing Fee Table (filed herewith)

     

     Item 9. Undertakings.

     

    The undersigned Registrant hereby undertakes:

     

    (a)(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

    (i)          To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii)         To reflect in the prospectus any facts or events arising after the effective date of this registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the ‘‘Calculation of Registration Fee’’ table in the effective registration statement;

     

    (iii)        To include any material information with respect to the plan of distribution not previously disclosed in this registration statement or any material change to such information in this registration statement;

     

    Provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this registration statement.

     

    - 4 -


     

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

    - 5 -


     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Mahwah, State of New Jersey, on August 12, 2025.

     

      KORU Medical Systems, Inc.
       
      By: /s/ Linda Tharby
        Name: Linda Tharby
        Title: Chief Executive Officer

     

    We, the undersigned officers and directors of KORU Medical Systems, Inc., hereby severally constitute and appoint Linda Tharby and Thomas Adams, and each of them singly, our true and lawful attorneys with full power to either of them, and to each of them singly, to sign for us and in our names in the capacities indicated below the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable KORU Medical Systems, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities indicated.

     

    Signature   Title   Date
             
    /s/ Linda Tharby   Chief Executive Officer and Director    
    Linda Tharby    (Principal Executive Officer)   August 12, 2025
             
    /s/ Thomas Adams   Chief Financial Officer    
    Thomas Adams   (Principal Financial Officer and Principal Accounting Officer)   August 12, 2025
             
    /s/ R. John Fletcher      
    R. John Fletcher   Chairman of the Board   August 12, 2025
             
    /s/ Robert Cascella        
    Robert A. Cascella   Director   August 12, 2025
             
    /s/ Donna French        
    Donna French   Director   August 12, 2025
             
    /s/ Joseph M. Manko, Jr.        
    Joseph M. Manko, Jr.   Director   August 12, 2025
             
    /s/ Shar Matin    
    Shahriar (Shar) Matin   Director   August 12, 2025
             
    /s/ Edward Wholihan      
    Edward Wholihan   Director   August 12, 2025

     

    - 6 -


    Get the next $KRMD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KRMD

    DatePrice TargetRatingAnalyst
    2/14/2025$4.50Overweight → Neutral
    Piper Sandler
    7/25/2024$4.00Buy
    B. Riley Securities
    9/7/2023$4.00Buy
    Lake Street
    9/7/2023$4.50Buy
    B. Riley Securities
    11/10/2022$3.00 → $4.00Hold → Buy
    Canaccord Genuity
    11/10/2022$3.00 → $3.50Neutral → Overweight
    Piper Sandler
    More analyst ratings

    $KRMD
    SEC Filings

    View All

    SEC Form S-8 filed by KORU Medical Systems Inc.

    S-8 - KORU Medical Systems, Inc. (0000704440) (Filer)

    8/12/25 6:54:59 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by KORU Medical Systems Inc.

    10-Q - KORU Medical Systems, Inc. (0000704440) (Filer)

    8/6/25 4:11:41 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    KORU Medical Systems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - KORU Medical Systems, Inc. (0000704440) (Filer)

    8/6/25 4:08:43 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    $KRMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    KORU Medical Systems Announces Q2 2025 Financial Results, Including Record Double-digit Revenue, and Raises 2025 Revenue Guidance

    KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the second quarter ended June 30, 2025. Financial Highlights •   Second quarter 2025 net revenues of $10.2 million, a 21% increase over the prior year period       •   Core business (Domestic and International) net revenues of $9.3 million, a 19% increase over the prior year period       •   Pharma Services and Clinical Trials (PST) net revenues of $0.9 mi

    8/6/25 4:05:00 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    KORU Medical Systems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced inducement equity awards to Adam Kalbermatten, Chief Commercial Officer, pursuant to his previously announced employment agreement with the Company dated as of June 30, 2025. Mr. Kalbermatten was granted nonqualified stock options on August 1, 2025 to purchase 600,000 shares of the Company's common stock at an exercise price of $3.44 per share. In addition, on July 28, 2025, his start date, Mr. Kalbermatten received 300

    8/1/25 4:55:00 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    KORU Medical Systems to Participate in the Canaccord Genuity 45th Annual Growth Conference

    KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the company will participate in the Canaccord Genuity 45th Annual Growth Conference on August 13th, 2025. KORU Medical's management is scheduled to present at the Canaccord Genuity 45th Annual Growth Conference on August 13, 2025, at 10:30 am ET. Interested parties can access the live and archived webcast on the News/Events page of the Investors section of KORU Medical's website at www.korumedical.com. About KORU

    7/30/25 4:05:00 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    $KRMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    KORU Medical Systems downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded KORU Medical Systems from Overweight to Neutral and set a new price target of $4.50

    2/14/25 8:08:51 AM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    B. Riley Securities resumed coverage on KORU Medical Systems with a new price target

    B. Riley Securities resumed coverage of KORU Medical Systems with a rating of Buy and set a new price target of $4.00

    7/25/24 8:28:49 AM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    Lake Street initiated coverage on KORU Medical Systems with a new price target

    Lake Street initiated coverage of KORU Medical Systems with a rating of Buy and set a new price target of $4.00

    9/7/23 9:12:10 AM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    $KRMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Manko Joseph M. Jr. bought $349,999 worth of shares (145,833 units at $2.40) and sold $349,999 worth of shares (145,833 units at $2.40) (SEC Form 4)

    4 - KORU Medical Systems, Inc. (0000704440) (Issuer)

    12/15/23 4:05:24 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    $KRMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by President and CEO Tharby Linda M

    4 - KORU Medical Systems, Inc. (0000704440) (Issuer)

    8/11/25 4:26:24 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Operating Officer Pazdan Christopher

    4 - KORU Medical Systems, Inc. (0000704440) (Issuer)

    8/11/25 4:25:19 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Financial Officer Adams Thomas Edward

    4 - KORU Medical Systems, Inc. (0000704440) (Issuer)

    8/11/25 4:24:02 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    $KRMD
    Leadership Updates

    Live Leadership Updates

    View All

    KORU Medical Systems Appoints Adam Kalbermatten as Chief Commercial Officer

    KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced the appointment of Adam Kalbermatten as Chief Commercial Officer, effective July 28, 2025. Adam brings over two decades of commercial leadership experience in the medical device and pharmaceutical industries, with a proven track record of scaling businesses, building high-performing teams, and delivering customer-focused innovation. As Chief Commercial Officer, he will oversee all aspe

    7/7/25 4:05:00 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    KORU Medical Systems to Join Russell 3000® and Russell 2000® Indexes

    KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company is set to join the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the Russell indexes annual reconstitution, effective after the US market opens on June 30, 2025, according to a preliminary list of additions posted Friday, June 6, 2025. The annual reconstitution of the Russell US indexes captures the 4,000 largest US stocks as of April 30, ranking them by tot

    6/11/25 4:05:00 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    KORU Medical Systems, Inc. Appoints Ken Miller as Chief Commercial Officer

    KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced the appointment of Ken Miller as Chief Commercial Officer, effective November 6, 2023. Ken brings over 30 years of extensive expertise and experience in leading high-performing teams in commercialization and marketing strategy, international expansion, and driving sustainable growth and profitability. As Chief Commercial Officer, Ken will have oversight of the global commercial functio

    11/8/23 4:08:00 PM ET
    $BDX
    $KRMD
    Medical/Dental Instruments
    Health Care

    $KRMD
    Financials

    Live finance-specific insights

    View All

    KORU Medical Systems Announces Q2 2025 Financial Results, Including Record Double-digit Revenue, and Raises 2025 Revenue Guidance

    KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the second quarter ended June 30, 2025. Financial Highlights •   Second quarter 2025 net revenues of $10.2 million, a 21% increase over the prior year period       •   Core business (Domestic and International) net revenues of $9.3 million, a 19% increase over the prior year period       •   Pharma Services and Clinical Trials (PST) net revenues of $0.9 mi

    8/6/25 4:05:00 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    KORU Medical Systems to Report Second Quarter 2025 Financial Results on August 6, 2025

    KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report second quarter 2025 financial results on Wednesday, August 6, 2025. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast Details The conference call can be accessed by dialing (877)-407-0784 for participants in the U.S. or Canada and (201)-689-8560 for internationa

    7/16/25 4:05:00 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    KORU Medical Systems Announces Record Q1 2025 Financial Results and Raises 2025 Revenue Guidance

    KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights First quarter 2025 net revenues of $9.6 million, an 18% increase over the prior year period Core business (Domestic and International) net revenues of $9.4 million, a 21% increase over the prior year period Gross profit of $6.0 million, a 19% increase over the prior year period, and gross margin of 62.8%, a 50-basis point improvement over th

    5/7/25 4:05:00 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    $KRMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by KORU Medical Systems Inc.

    SC 13G/A - KORU Medical Systems, Inc. (0000704440) (Subject)

    11/14/24 7:00:30 AM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by KORU Medical Systems Inc.

    SC 13G/A - KORU Medical Systems, Inc. (0000704440) (Subject)

    11/13/24 4:23:54 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by KORU Medical Systems Inc.

    SC 13G - KORU Medical Systems, Inc. (0000704440) (Subject)

    5/23/24 7:00:28 AM ET
    $KRMD
    Medical/Dental Instruments
    Health Care